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Abstract
The present study analyzed outcomes of surgery followed by concomitant chemoradiotherapy (CCRT) with temozolomide (TMZ) in
patients with newly diagnosed glioblastoma (GBM) at a single institution. Outcomeswere retrospectively reviewed in 252 consecutive
patients with newly diagnosed GBM who underwent surgery followed by CCRT with TMZ at the authors’ institution between 2005
and 2013. At initial operation, 126 (50.0%), 55 (21.8%), 45 (17.9%), and 26 (10.3%) patients underwent gross total resection (GTR),
subtotal resection, partial resection (PR), and biopsy, respectively. Their median overall survival (OS) was 20.8 months (95%
conﬁdence interval [CI] 17.7–23.9 months) and their median progression-free survival was 12.7 months (95% CI 11.2–14.2 months).
The O6-methylguanine-DNAmethyltransferase (MGMT) promoter was methylated in 78 (34.1%) of the 229 patients assayed, and an
isocitrate dehydrogenase 1 mutation was detected in 7 (6.6%) of the 106 patients analyzed. Univariate analyses showed that patient
age, involvement of eloquent areas, involvement of the subventricular zone, presence of leptomeningeal seeding, Karnofsky
Performance Status, extent of resection (EOR), MGMT promoter methylation, and presence of an oligodendroglioma component
were prognostic of OS. Multivariate analysis showed that age, involvement of eloquent areas, presence of leptomeningeal seeding,
EOR, and MGMT promoter methylation were signiﬁcantly predictive of survival. OS in patients with GBM who undergo surgery
followed by CCRT with TMZ is enhanced by complete resection. Other factors signiﬁcantly prognostic of OS include that age,
involvement of eloquent areas, presence of leptomeningeal seeding, and MGMT promoter methylation.
Abbreviations: CCRT = concomitant chemoradiotherapy, EOR = extent of resection, GBM = glioblastoma, GTR = gross total
resection, IDH = isocitrate dehydrogenase, KPS = Karnofsky performance status, MGMT = O6-methylguanine-DNA
methyltransferase, MRI = magnetic resonance imaging, OS = overall survival, PFS = progression-free survival, STR = subtotal
resection, SVZ = subventricular zone, TMZ = temozolomide.
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11. Introduction
Glioblastoma (GBM) is the most malignant and common
primary brain tumor in adults. Standard therapy of patients
with newly diagnosed GBM includes resection followed by
concomitant chemoradiotherapy (CCRT) and adjuvant temozo-
lomide (TMZ).[1] Despite treatment, however, the median overall
survival (OS) of patients with GBM is only 14.6 to 21.1
months.[2,3]
Characteristics prognostic of survival in patients with GBM
include clinical factors such as age, performance score, and extent
of resection (EOR), along with factors associated with tumor
location, such as invasion of eloquent areas or the subventricular
zone (SVZ) and coexistence of leptomeningeal seeding.[4–6]
Survival rate is strongly dependent on treatment modality;
adjuvant chemoradiotherapy with TMZ is considered standard
because it signiﬁcantly increases patient survival rate. Further-
more, advances in surgical techniques and technology have been
reported to improve survival.[7,8]
Molecular prognostic factors in GBM include mutations in
the genes encoding isocitrate dehydrogenase (IDH) 1/2 and
methylation of the O6-methylguanine-DNA methyltransferase
[9,10]
Roh et al. Medicine (2017) 96:27 Medicine(MGMT) promoter. MGMT promoter methylation has also
been found to predict response to TMZ-based chemotherapy.[9]
A meta-analysis published in 2014, which investigated the
prognostic value of MGMT promoter methylation in different
races, reported that, in Asians, MGMT promoter methylation
was not related to OS by univariate analysis or to progression-
free survival (PFS) by multivariate analysis.[11] However, this
meta-analysis included only 6 studies in Asians, compared with
46 in Caucasians, as only a few studies have reported molecular
information on GBM in Asian patients.[12]
To assess the survival beneﬁts of standard treatment, this study
analyzed 252 consecutive GBM patients who underwent surgery
followed by standard chemoradiotherapy (CCRT) plus TMZ at a
single institution. The associations of MGMT promoter
methylation and IDH1 mutation status with survival were also
investigated.
2. Materials and methods
2.1. Patient recruitment
The present retrospective studywas approved by our institutional
review board, which waived the requirement for patient informed
consent due to the retrospective nature of this study (2015-2474-
001). All patients coded as having GBM histology at Yonsei
University Severance Hospital from 2005 to 2013 were screened.
Subjects were included if they had been histologically diagnosed
with GBM according to the World Health Organization (WHO)
classiﬁcation of central nervous system tumors,[13] as conﬁrmed
by 2 pathologists (SHK and JC). Patients having GBM with
oligodendroglioma component (GBMO) and giant cell GBM
(GCGBM) were also included. Patients were excluded if
preoperative or follow-up images were unavailable, if they were
aged <18 years, if they had coexisting malignancy or
gliosarcoma. Patients and their guardians were informed of
treatment options before surgery and when pathological
diagnosis was obtained after surgery. The patients who agreed
to start standard CCRT with TMZ were included in the analysis.
All patients were followed up until death or the time of analysis
(August 2016).
2.2. Treatment protocols
Tumors were removed following the protocol of maximal safe
resection, except for patients who underwent biopsy. Most
patients underwent navigation-guided surgery, using intraoper-
ative magnetic resonance imaging (MRI) in 39 patients and 5-
aminolevulinic acid in 74. Diffusion tensor image tractography
was used for navigation in patients with tumors located adjacent
to areas of motor, vision, and language functions to minimize
possible damage. Awake craniotomy was performed in 24
patients. Most patients (87%) started CCRT with using Stupp
regimen (daily 75mg/BSA of TMZ plus 60Gy of radiotherapy
fractionated 2Gy/d) within 3 weeks of surgery.[1] Twenty-eight
days following the completion of CCRT, TMZ was started; 6
cycles were administered unless adverse event or progression was
detected.
In cases of recurrence, reoperation was considered a priority,
when the tumor was resectable. Maximal safe resection was
attempted using the method used for initial surgery. Repeat
radiotherapy was again recommended after surgery. If the
recurrent tumor was considered unresectable, due to deep
location, involvement of eloquent areas, or small size, gamma-
knife radiosurgery was recommended. Adjuvant TMZ adminis-2tration was also considered following repeat radiotherapy. If the
tumor rerecurred, bevacizumab was considered as salvage
treatment.2.3. Image analysis
All patients underwent pre- and postoperative MRI, with images
stored in a picture archiving and communication system. Images
were assessed and reviewed by 2 experienced radiologists.
Parameters evaluated preoperatively included tumor size (maxi-
mal diameter of enhancing lesion), primary lesion location,
relationship to eloquent areas, SVZ involvement, and leptome-
ningeal seeding. The size of the tumor was classiﬁed using cutoff
value of 3.4cm, chosen by Contal and O’Quigley method.[14]
The EOR was determined by early (<48 hours) postoperative
MRI. Gross total resection (GTR) was deﬁned as the absence of a
residual lesion, based on T1-weighted contrast enhancement
images. When the tumor was left in the surgical ﬁeld, the tumor
was considered to have undergone a STR even if no tumor was
seen in the postoperative MRI ﬁndings. Subtotal resection (STR)
was deﬁned as the presence of a residual tumor but EOR was
>90%. Partial resection (PR) was deﬁned as the presence of
>10% of tumors (EOR <90%). In the case of a discrepancy,
3 observers (THR, MCO, and JHC) simultaneously reviewed the
images to achieve consensus.
Follow-up MRIs were performed before the start of the ﬁrst
and fourth TMZ cycles and 1 month after the end of the sixth
cycle. Patients underwent follow-up MRI every 3 months for the
ﬁrst 2 years, and every 6 or 12 months thereafter. Patients
suspected of disease progression, as deﬁned by RANO criteria,
underwent immediate MRI.[15]
A transient progressive lesion within 3 months after radiother-
apy was considered pseudoprogression. Patients with an
apparent newly appearing enhancing mass were assessed by
MR spectroscopy, 11C-methionine positron emission tomogra-
phy, or perfusionMRI to differentiate between radiation necrosis
and recurrence.2.4. Molecular analysis
Genomic DNA was isolated from parafﬁn-embedded samples of
229 patients. The DNA methylation status of the CpG islands at
the MGMT promoter was determined by methylation-speciﬁc
polymerase chain reaction, as described, with some modiﬁca-
tions.[16,17]
Representative tissue sections were assessed by immunohis-
tochemistry, using a Ventana BenchMark XT autostainer
(Ventana Medical System, Inc. Tucson, AZ) according to the
manufacturer’s protocols. Primary antibodies included anti-
human IDH1 R132Hmouse monoclonal (clone H09L, Dianova,
1:80 dilution) and anti-Ki-67 (clone Mib-1, Dako, 1:150
dilution). Samples showing cytoplasmic expression of IDH1
R132H in glioma cells were classiﬁed as positive for mutation,
with all others classiﬁed as “wild-type.” MIB-1 (Ki67) score was
deﬁned as the percentage of positive nuclei among 1000 tumor
cells, or as many as possible in the case of small specimens.2.5. Statistical analysis
Survival outcomes were analyzed by the Kaplan–Meier method
and compared by the log-rank test. Multivariate Cox propor-
tional hazards models were created to test for associations of
factors with PFS andOS. In thesemodels, EORwas dichotomized
Table 1
Patient characteristics.
Age, y 57 (19.0–82.0)
Sex
Female 131 (52.0)
Male 121 (48.0)
Roh et al. Medicine (2017) 96:27 www.md-journal.comas complete (gross total) versus incomplete (subtotal, partial, and
biopsy). All statistical tests were 2-sided, and the threshold for
statistical signiﬁcance was P< .05. All analyses were performed
with SPSS forWindows version 20.0 (SPSS Inc., Chicago, IL) and
SAS version 9.2 (SAS Institute Inc., Cary, NC).Location
Left 101 (40.1)
Right 123 (48.8)
Bilateral 22 (8.7)
Central 6 (2.4)
Size, cm, mean±SD 4.65±1.55
KPS (median)
Preoperative 70
Postoperative 70
MGMT promoter status (n=229)
Methylated 78 (34.0)
Unmethylated 151 (66.0)
IDH1 mutation (n=106)
Yes 99 (93.4)
No 7 (6.6)
Pathology
Glioblastoma 213 (84.5)
GCGBM 10 (4.0)
GBMO 29 (11.5)
Early discontinuation of CCRT 4 (1.6)
Adjuvant temozolomide
0 22 (8.7)
1–3 41 (16.3)
4–6 141 (56.0)
7+ 48 (19.0)3. Results
3.1. Patient characteristics and overall survival
Between January 2005 to December 2013, 313 patients newly
diagnosed with pathologically proven GBM were treated at
Yonsei University Severance Hospital. Sixty-one patients were
excluded, including 11 aged <18 years, 21 who were lost to
follow-up, 4 who had a coexisting malignancy, 4 who died of
pneumonia before CCRT, 7 who refused CCRT, 13 who received
only radiotherapy, and 1 who received TMZ alone. Finally, 252
patients were included in the analysis.
The characteristics of the included patients are shown in
Table 1. The median time from diagnosis to the start of CCRT
was 20 days 4 to 6 (range, 8–47 days). The median therapeutic
dose of radiation was 60Gy (range, 7.2–84Gy). The median
follow-up period was 20.8 months, and 212 (84.1%) patients
died during the study period. The median OS was 20.8 months
(95% conﬁdence interval [CI]: 17.7–23.9 months), and the
median PFS was 12.7 months (95% CI: 11.2–14.2 months). The
actuarial 1-, 3-, and 5-year OS rates were 79.8%, 28.2%, and
16.2%, respectively, and the actuarial 1-, 3-, and 5-year PFS rates
were 54.1%, 14.4%, and 6.1%, respectively.Values are presented as number (%) or median (range) unless otherwise indicated. CCRT =
concomitant chemoradiotherapy, IDH = isocitrate dehydrogenase, KPS = Karnofsky performance
status, MGMT = O6-methylguanine-DNA methyltransferase.3.2. Clinical factors and prognostic relevance
The prognostic relevance of the clinical parameters is summarized
in Table 2. As predicted, patients aged <50 years showed better
prognosis than those aged≥50 years. OSwas signiﬁcantly shorter
in patients having lesions located in eloquent areas or with SVZ
involvement, subependymal enhancement, or leptomeningeal
dissemination. Using 3.4cm as the cutoff-value, tumor size was
unrelated to either OS and PFS. A Karnofsky performance status
(KPS) score ≥80 was associated with improved OS, but not PFS.
At initial operation, 126 (50.0%), 55 (21.8%), 45 (17.9%),
and 26 (10.3%) patients underwent GTR, STR, PR, and biopsy,
respectively. Both OS and PFS were higher in subjects who
underwent GTR than in those who underwent STR, PR, and
biopsy. Median OS was 27.9 months (95% CI, 22.8–32.9
months) in patients who underwent GTR, but there were no
differences in OS or PFS among patients who underwent STR,
PR, and biopsy (Fig. 1). Patients who underwent GTR had 1-, 3-,
and 5-year OS rates of 91.3%, 38.6%, and 25.3%, respectively,
whereas patients who underwent incomplete resection (STR, PR,
and biopsy) had 1-, 3-, and 5-year OS rates of 68.0%, 17.6%,
and 7.2%, respectively.
MGMT promoter methylation was detected in 78/229
(34.1%) patients and was associated with superior PFS and
OS. MGMT status was not determined in 23 patients due to
insufﬁcient amount of tissue. Most of these patients (18/23) were
who had undergone biopsy alone. IDH1mutations were found in
7/106 (6.6%) patients. The median OS for patients with mutated
and wild-type IDH1 were 67.1 and 21.1 months, respectively
(P= .138). Ki67 labeling index was not associated with PFS or
OS. Patients with GCGBMs did not differ from those with GBM
in either PFS or OS, whereas patients with GBMO showed
signiﬁcantly longer PFS and OS than other patients.33.3. Multivariate analysis for outcome
Univariate analyses showed that factors signiﬁcantly prognostic
of OS and PFS included patient age, KPS, EOR, MGMT
promoter methylation status, eloquent area involvement, SVZ
involvement, and leptomeningeal seeding. In performing multi-
variate logistic regression analysis, patients with missing values
were excluded; therefore, multivariate analysis included only the
229 patients with known MGMT promoter methylation status.
Young age (<50 years), GTR, subependymal enhancement on
preoperative MRI, and MGMT promoter methylation were
found to be independently prognostic factors for both PFS and
OS (Table 3), whereas eloquent area involvement and leptome-
ningeal dissemination were signiﬁcantly prognostic only for OS.3.4. Overall survival related to 3 signiﬁcant prognostic
factors
Treatment outcome was analyzed in 8 groups of patients
stratiﬁed by the 3 most signiﬁcant prognostic factors; age,
MGMT promoter methylation, and EOR (Table 4). The median
OS of the 13 patients with methylated MGMT, young age
(<50 years), and GTR was 67.1 months (range, 12.7–121.5
months). In contrast, the median OS of the 45 patients with an
unmethylated MGMT gene, older age (≥50 years), and less than
STR was 14.8 months.
4. Discussion
Clinical factors considered signiﬁcantly prognostic for survival in
patients with GBM include age, performance status, EOR, tumor
Table 2
Univariate analyses of factors prognostic for OS and PFS.
PFS, mo OS, mo
Variable N Median (95% CI) P Median (95% CI) P
All patients 252 12.7 (11.2–14.2) 20.8 (17.7–23.9)
Age group
Younger (<50y) 75 15.0 (12.5–17.5) 28.8 (22.3–35.3)
Older (≥50y) 177 11.5 (10.2–12.8) .025 17.5 (14.6–20.4) .003
Eloquent area involvement
Noneloquent 89 14.7 (10.9–18.5) 24.7 (20.9–28.5)
Near-eloquent 40 12.7 (9.2–16.2) .067 18.5 (14.6–22.4) .058
Eloquent 123 11.3 (10.0–12.6) .013 18.1 (13.9–22.3) .002
Subventricular zone involvement
No involvement 106 14.4 (11.1–17.7) 24.2 (18.5–29.9)
Touching ventricle 146 11.2 (8.6–13.8) .006 18.1 (14.9–21.3) .032
Leptomeningeal seeding
No 207 13.6 (12.2–15.0) 22.5 (19.6–25.4)
Subependymal enhancement 33 7.2 (3.9–10.5) <.001 14.9 (13.7–16.1) <.001
Cortical enhancement 6 5.8 (2.9–8.7) .153 8.2 (1.6–14.8) .657
Deﬁnite Seeding 6 6.1 (0.2–12.0) .040 7.0 (0.2–13.8) <.001
Maximum diameter
<3.4 cm 51 16.9 (10.9–22.9) 30.2 (18.6–41.8)
≥3.4 cm 201 12.3 (10.9–13.7) .062 18.3 (15.7–20.9) .097
Preoperative KPS (%)
≥80 111 13.1 (11.0–15.2) 23.5 (17.4–29.6)
<80 141 12.3 (10.5–14.1) .394 18.3 (14.7–21.9) .023
Extent of resection
Total resection 126 16.4 (13.7–19.1) 27.9 (22.8–32.9)
Subtotal resection 55 9.0 (6.0–12.0) <.001 15.8 (12.7–18.9) <.001
Partial resection 45 9.1 (4.1–14.0) .001 15.5 (12.5–18.5) .003
Biopsy 26 8.3 (4.5–12.1) <.001 17.2 (12.1–22.3) .005
MGMT promoter methylation (n=229)
Yes 78 19.6 (12.3–26.9) 33.2 (25.8–40.6)
No 151 11.8 (10.2–13.4) <.001 17.4 (14.4–20.4) <.001
IDH1 mutation (n=106)
Yes 7 29.1 (0.0–62.2) 67.1 (0.0–146.7)
No 99 13.1 (11.8–14.4) .073 21.1 (15.1–27.1) .138
Ki67 labeling index (n=117)
<20.0 58 12.0 (10.1–13.9) 21.5 (14.6–28.4)
≥20.0 59 14.1 (13.0–15.2) .721 23.5 (15.0–32.0) .787
Pathology
GBM 213 12.1 (10.7–13.5) 19.4 (16.3–22.5)
GCGBM 10 10.2 (0.0–30.6) .197 26.7 (0.0–75.7) .149
GBMO 29 17.1 (7.1–27.1) .003 28.8 (16.1–41.5) .013
CI = conﬁdence interval, CSF = cerebrospinal ﬂuid, GBM = glioblastoma, GBMO = glioblastoma with oligodendroglioma component, GCGBM = giant cell glioblastoma, IDH = isocitrate dehydrogenase,
KPS = Karnofsky performance status, MGMT = O6-methylguanine-DNA methyltransferase, OS = overall survival, PFS = progression-free survival, SVZ = subventricular zone.
Figure 1. Kaplan–Meier analysis of the effects of extent of resection on progression-free survival (PFS) (A) and overall survival (B). Total resection signiﬁcantly
beneﬁted PFS and overall survival when compared with subtotal resection, partial resection, and biopsy (P< .001 each).
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Table 3
Multivariate analyses of factors prognostic for OS and PFS.
Progression Death
Relative risk (95% CI) P Relative risk (95% CI) P
Younger age (<50y) 0.64 (0.47–0.88) .006 0.57 (0.41–0.78) .001
Eloquent area
Eloquent area involvement 1.25 (0.90–1.76) .187 1.71 (1.22–2.41) .002
Near-eloquent area involvement 1.13 (0.74–1.75) .570 1.46 (0.94–2.26) .092
Leptomeningeal seeding
Subependymal enhancement 1.87 (1.21–2.90) .005 1.92 (1.24–2.99) .004
Cortical enhancement 2.24 (0.90–5.56) .082 0.80 (0.29–2.21) .671
Disseminated 1.72 (0.73–4.07) .216 4.12 (1.73–9.82) .001
Gross total resection 0.48 (0.35–0.65) <.001 0.60 (0.44–0.81) .001
MGMT promoter methylation 0.56 (0.41–0.76) <.001 0.58 (0.43–0.80) .001
CI = conﬁdence interval, MGMT = O6-methylguanine-DNA methyltransferase.
Table 4
Relationships among 3 factors signiﬁcant prognostic of OS.
Age group MGMT promoter methylation status EOR N Median OS P
<50 Methylated GTR 13 67.1 (12.7–121.5) .014
STR+PR+biopsy 7 36.6 (27.8–45.4)
Unmethylated GTR 21 37.2 (17.5–56.9) .006
STR+PR+biopsy 30 15.9 (8.4–23.4)
≥50 Methylated GTR 38 32.8 (24.6–41.0) .213
STR+PR+biopsy 20 17.5 (11.8–23.2)
Unmethylated GTR 55 16.9 (11.7–22.1) .005
STR+PR+biopsy 45 14.8 (13.2–16.4)
CI = conﬁdence interval, EOR = extent of resection, GTR = gross total resection, MGMT = O6-methylguanine-DNA methyltransferase, OS = overall survival, PR = partial resection, STR = subtotal resection.
Roh et al. Medicine (2017) 96:27 www.md-journal.comlocation, degree of necrosis, and enhancement on preoperative
MRI.[6] Because the treatment modality inﬂuences the survival
rate, we analyzed only those patients who agreed to start
standard therapy (CCRT plus TMZ). The median OS of GBM
patients who underwent TMZ-based CCRT reported in large
prospective studies is shown in Table 5.
The median OS and PFS of all patients in this study were 20.8
and 12.7 months, much higher than the 14.6 and 6.9 months
reported in the EORTC/NCIC study.[1] One plausible cause for
this discrepancy may have been the higher percentage of patients
in our study who underwent total resection. In our study, 50% of
subjects underwent GTR, with a median OS of 27.9 months,
signiﬁcantly higher than the median OS of the patients whoTable 5
Literature ﬁndings of patient characteristics, PFS, OS, and EOR in p
Author Year Study region No. of patients
Stupp et al[1] 2005 Europe
∗
287
Lai et al[3] 2011 USA 110
Oike et al[27] 2013 Japan 45
Kreth et al[28] 2013 Germany 222
Yang et al[11] 2013 China 226
Chinot et al[29] 2014 Europe† 463
Gilbert et al[30] 2014 USA‡ 309
Grabowski et al[31] 2014 USA 128
This study 2016 Korea 252
Values are presented as number (%) or median months unless otherwise indicated. GTR = gross total
∗
EORTC-NCIC, The European Organization for Research and Treatment of Cancer/National Cancer Insti
† AVAGlio, The Avastin in Glioblastoma.
‡ RTOG, Radiation Therapy Oncology Group.
5underwent STR, PR, and biopsy. In the EORTC/NCIC study,
approximately 40% of patients underwent GTR; however, that
report provided limited information regarding the method used
to select patients for GTR. In our study, the criteria for GTRwere
thoroughly assessed through intraoperative ﬁndings and post-
operative MRI within 48 hours. In addition, we performed so-
called supratotal resection when tumors were conﬁned in
noneloquent areas, removing as much of the brain as possible
from adjacent tumors unless they affect function.[18] A future
study will assess the survival beneﬁts of supratotal resection.
Salvage treatment after recurrence could also have contributed
to longer OS. Of the 217 patients with recurrent GBM, 44
underwent a second operation, 4 underwent a third operation,atients with GBM.
No. of GTR PFS OS OS of GTR group
113 (39.4) 6.9 14.6 18.8
47 (42.7) 7.6 21.1 –
7 (15.6) – 15.8 –
92 (41.4) 7.8 17.1 21
102 (45.1) 8.8 14.4 –
196 (42.3) 6.2 16.7 –
7.3 16.1 –
57 (44.5) – 13.8 19
126 (50.0) 12.7 20.8 27.9
resection, OS = overall survival, PFS = progression-free survival, STR = subtotal resection.
tute of Canada.
Roh et al. Medicine (2017) 96:27 Medicineand 1 underwent a fourth operation for recurrent lesions. In
addition, 21 patients underwent repeat radiation treatment or
gamma knife surgery for recurrent lesions, and 48 were
administered more than 6 cycles of adjuvant TMZ, with the
latter treated with a median of 11 cycles (range, 7–24 cycles).
Eight patients were treated with bevacizumab plus irinotecan for
recurrent lesions. Studies are needed to analyze the effects of
salvage treatments in patients with recurrent GBM.
Our results also conﬁrmed that EOR is one of the most
signiﬁcant independent prognostic factors for both PFS and
OS.[5,19–22] This factor is important, as it is the only prognostic
factor adjustable by surgeons.
Several studies have reported that patients with GBMO have a
better prognosis than those with GBM, and that GBMO is
associatedwith a 1p/19q co-deletion.[23] In contrast, other studies
have reported no correlation between GBMO and 1p/19q co-
deletion or survival.[24] We observed differences in PFS and OS
between patients with GBMO and those with GBM. The updated
WHO classiﬁcation in 2016 eliminated the category of GBMO,
with these tumors now classiﬁed as GBM or anaplastic
oligodendroglioma according to the IDH mutation and 1p/19q
co-deletion. However, the patients in the present study were
diagnosed before the WHO classiﬁcation was updated, and 15%
of patients the EORTC_26981/NCIC_CE.3 trial had GBMO.[24]
IDHmutation is an important genetic marker in gliomas. IDH-
mutant GBMs are known to show much better prognosis than
IDH-wildtype GBMs.[10] According to the WHO classiﬁcation of
tumors of the central nervous system published in 2016, GBM
with IDH mutation is classiﬁed as a different entity from GBM
with IDH-wildtype.[25] In our study, IDHmutationwas examined
in 42%of patients who performed immunohistochemical staining
for IDH1 R132H. It is rare that adult GBM has mutations other
than IDH1 R132H.[26] Even if some of the untested younger
patients have IDH mutations, there is little chance of causing a
signiﬁcant change in the median survival. Among the examined
patients, 6.6% had IDHmutation on the immunohistochemistry,
similar to what is known in other studies. In addition, the other
studies aboutGBMbeforeWHO2016 classiﬁcation also included
IDH-mutant GBM in survival analysis.
We also conﬁrmed that MGMT promoter methylation is an
independent prognostic factor of survival in patients with
GBM.[9,12] Both PFS and OS were signiﬁcantly higher in patients
with MGMT methylation compared to those without such
methylation. TMZ has been shown to enhance survival beneﬁts
in patients receiving CCRT, a ﬁnding supported in our study, in
that most completed CCRT when TMZ was also administered.
The present study had several limitations, including its
retrospective design, which may introduce selection bias. Four
patients with newly diagnosed GBM were not eligible to start
CCRT due to pneumonia. Thirteen patients, most of older age,
received radiotherapy alone without TMZ. These patients were
excluded from the analysis. However, the characteristics of
patients in this study, including median age, age distribution, and
performance status, were similar to those of patients in previous
studies, such as the EORTC/NCIC trial, who received CCRT.
Therefore, this limitation was not considered to have affected our
comparison of OS.5. Conclusion
The survival rate in patients with GBM is improved with surgery
followed by CCRT plus TMZ. We also conﬁrmed that age,
MGMT promoter methylation status, tumor extent, and EOR6are signiﬁcant prognostic factors for survival in GBM patients.
Further, we found that EOR was the only modiﬁable prognostic
factor, suggesting that maximum safe resection can improve
overall outcome in patients with GBM.References
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